HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according ...

Early diagnosis and prompt antiretroviral therapy initiation are critical for children due to the rapid progression of HIV in ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...

Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...